Key Points
ALTHE.PA stock surged 31% to €0.623 on exceptional 694K share volume.
Theraclion develops non-invasive echotherapy for varicose veins and thyroid treatment.
Company faces profitability challenges with negative earnings and cash flow metrics.
Meyka AI forecasts 64% upside to €1.02 within 12 months with B-grade rating.
Theraclion SA’s ALTHE.PA stock delivered a powerful 31% gain on May 6, 2026, closing at €0.623 on EURONEXT with exceptional trading volume. The French medical device company saw 693,860 shares trade, far exceeding its typical daily average of 45,829. This surge marks a significant move for the healthcare innovator, which develops echotherapy solutions using high-intensity focused ultrasound technology. The stock’s strong performance reflects renewed investor interest in the company’s non-invasive treatment platforms for varicose veins and thyroid conditions.
ALTHE.PA Stock Price Movement and Trading Activity
ALTHE.PA stock opened at €0.489 and climbed to a day high of €0.70, delivering a €0.147 gain from the previous close of €0.476. The 31% jump represents one of the strongest single-day performances for Theraclion SA in recent months.
Trading Volume Surge
Volume exploded to 693,860 shares, representing a 1,412% increase above the 50-day average of 45,829. This exceptional activity signals strong institutional and retail participation. The stock’s 50-day moving average sits at €0.509, while the 200-day average stands at €0.627, placing today’s close near longer-term resistance levels.
Market Sentiment and Technical Indicators
Technical analysis reveals mixed signals for ALTHE.PA stock. The Relative Strength Index (RSI) stands at 46.13, indicating neutral momentum without overbought conditions. The Money Flow Index (MFI) reads 34.21, suggesting weak buying pressure despite the volume surge.
Liquidation and Momentum Concerns
The Commodity Channel Index (CCI) at -54.74 signals potential oversold conditions, while Williams %R at -77.86 indicates extreme weakness. On-Balance Volume (OBV) shows -614,427, reflecting net selling pressure beneath the surface. These divergences suggest the rally may face resistance at higher levels.
Theraclion SA Fundamentals and Valuation
Theraclion SA operates in the Medical – Devices sector within Healthcare, employing 280 people from its Malakoff, France headquarters. The company’s market capitalization reached €22.69 million with 47.16 million shares outstanding. Track ALTHE.PA on Meyka for real-time updates on this medical device innovator.
Financial Challenges
The company faces significant headwinds. Net income per share stands at -€0.098, while earnings yield is -20.34%. The price-to-sales ratio of 19.13 appears stretched given negative profitability. Year-to-date, ALTHE.PA stock has declined 20.1%, though it’s up 100.4% over the past year from much lower levels.
Meyka AI Stock Grade and Price Forecast
Meyka AI rates ALTHE.PA with a grade of B, suggesting a HOLD recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The overall score of 67.28 reflects balanced risk-reward dynamics for the medical device sector.
Forward Price Projections
Meyka AI’s forecast model projects ALTHE.PA stock reaching €1.02 within 12 months, implying 64% upside from current levels. Three-year forecasts suggest €1.84, while five-year targets point to €2.67. Forecasts are model-based projections and not guarantees. These grades are not guaranteed and we are not financial advisors.
Final Thoughts
ALTHE.PA stock delivered a remarkable 31% rally on May 6, driven by exceptional trading volume that exceeded daily averages by over 1,400%. While the technical setup shows mixed signals with oversold indicators and negative volume flow, the stock’s movement reflects renewed market interest in Theraclion SA’s echotherapy innovations. The company’s B-grade rating and 64% upside forecast to €1.02 suggest cautious optimism, though persistent profitability challenges warrant careful monitoring. Investors should track earnings announcements scheduled for October 26, 2026, as they’ll provide critical insight into the company’s commercial progress and cash burn trajectory.
FAQs
Exceptional trading volume of 693,860 shares, far exceeding daily averages, drove the surge. No specific catalyst was announced, but the move suggests renewed institutional interest in Theraclion’s echotherapy technology for varicose veins and thyroid conditions.
Theraclion develops non-invasive echotherapy solutions using high-intensity focused ultrasound. Key products include SONOVEIN for varicose veins, ECHOPULSE for thyroid nodules and breast fibroadenoma, and EPack disposables.
No. Theraclion reported negative net income per share of -€0.098 and negative earnings yield of -20.34%, typical for early-stage medical device innovators in development phases.
Meyka AI projects ALTHE.PA reaching €1.02 within 12 months (64% upside from €0.623), with three-year and five-year forecasts of €1.84 and €2.67 respectively. These are model-based projections, not guarantees.
Theraclion’s earnings announcement is scheduled for October 26, 2026, providing updates on commercial progress, cash burn, and the company’s path toward profitability.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)